Modulation of purine metabolism and uric acid level by gut microbiota product, Acetate; in Streptozotocin-induced diabetes mellitus in male wistar rats

Abstract

Sodium acetate is a gut microbiota product which has shown potential metabolic benefits on several disease models. Several studies have revealed that gut microbiota products enhance insulin sensitivity, improve glucose uptake and suppress cardiometabolic alterations in Diabetes Mellitus (DM). However, acetate influence on purine metabolism in DM has not been fully explored. The aim this study was to investigate the effect of acetate on blood glucose level, insulin sensitivity, purine metabolism and uric acid level in streptozotocin-induced diabetes. A total of thirty (30) male Wistar rats of about 8-10 weeks weighting between 140g-220g were used for the study. Group 1: control. Group 2: Diabetic (untreated). Group 3: sodium acetate (200 mg/kg orally). Group 4: Metformin group (100 mg/kg orally). Group 5: Diabetic with sodium acetate (200 mg/kg). Group 6: Diabetic + metformin (100 mg/kg). All groups were treated for 21 days (n= 5/group). The findings from this study showed that sodium acetate enhanced insulin sensitivity, xanthine oxidase/adenosine deaminase activities and uric acid level (p< 0.05) in comparison to the diabetic control rats. The results of this study suggest the beneficial effect of acetate by modulating purine metabolism via adenosine deaminase/xanthine oxidase and uric acid pathway in diabetes mellitus.